Trump executive order on veteran research: what it actually does
55 replies · Legal & Policy
There's been a lot of confusion about what the executive order on psychedelic research for veterans actually does and doesn't do. Let me try to be precise, because both the hype and the dismissal seem overblown.
What it actually does:
— Directs VA, DoD, and HHS to prioritize and fund clinical trials of psychedelic-assisted therapies
— Establishes interagency coordination across VA, DoD, HHS, and ONDCP
— Directs FDA to review its Breakthrough Therapy process for psychedelic compounds
— Requires progress reporting on defined timelines
What it does not do:
— Does not reschedule psilocybin or MDMA — both remain Schedule I
— Does not create a VA treatment program — veterans cannot walk in and get psilocybin
— Does not override the FDA approval process
— Does not change the MDMA Complete Response Letter situation
The practical effect for veterans in 2026: more clinical trial enrollment slots at VA facilities. That's real and meaningful for people who qualify. It is not access.
The distinction between 'research acceleration' and 'treatment access' is the key one that gets lost. These are very different things. Research acceleration is good and real. Treatment access requires rescheduling and FDA approval, neither of which this order produces.
As a veteran: I appreciate the signal and the research funding. What I actually need is VA-administered treatment for the veterans who can't access Oregon or Colorado. That's still not here.
The FDA directional piece is the most potentially consequential long-term. If FDA streamlines its review process for psychedelics, that could shorten the approval timeline by 1–2 years. That's not nothing.
52 more replies — forum posting coming soon.